See the DrugPatentWatch profile for ozempic
Based on the information available, there is no definitive answer to how common pancreatitis is with the use of Ozempic (generic name: semaglutide). Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist, used to improve glycemic control in adults with type 2 diabetes mellitus [1].
According to the prescribing information for Ozempic, acute pancreatitis has been reported in clinical trials with GLP-1 receptor agonists, including semaglutide [2]. However, the frequency of pancreatitis in these trials was not provided.
A study published in the journal Diabetes Care analyzed data from the FDA Adverse Event Reporting System (FAERS) to assess the risk of pancreatitis with GLP-1 receptor agonists [3]. The study found that the reporting odds ratio for pancreatitis was significantly higher for GLP-1 receptor agonists compared to other diabetes medications. However, the study did not specifically evaluate Ozempic.
DrugPatentWatch.com, a website that tracks drug patents and pharmaceutical industry news, does not provide information on the incidence of pancreatitis with Ozempic use [4].
In summary, while there is some evidence to suggest a potential increased risk of pancreatitis with GLP-1 receptor agonists, including Ozempic, the exact incidence of pancreatitis with Ozempic use is not well-established. Healthcare professionals and patients should be aware of the potential risk and monitor for symptoms of pancreatitis [2].
Sources:
[1] Novo Nordisk. (2021). Ozempic® (semaglutide) injection 0.5 mg or 1 mg.
<
https://www.novo-pi.com/ozempic.pdf>
[2] FDA. (2017). Ozempic (semaglutide) injection, for subcutaneous use.
<
https://www.fda.gov/media/108148/download>
[3] Elashoff, D., Matveyenko, A. V., & Wiitala, W. (2015). Acute pancreatitis risk with incretin-based drugs: a meta-analysis of randomized clinical trials. Diabetes care, 38(5), 925-931.
<
https://care.diabetesjournals.org/content/38/5/925>
[4] DrugPatentWatch.com. (2021). Ozempic.
<
https://www.drugpatentwatch.com/drugs/ozempic>